Hikma, Bio-Thera enter exclusive agreement for monoclonal antibody
27th Aug 2021 12:32
(Sharecast News) - Bio-Thera Solutions and Hikma Pharmaceuticals have entered into a commercialisation and license agreement to commercialise a monoclonal antibody used for the treatment of Crohn's disease.
Read moreHikma lifts FY generics guidance as first-half profits, revenue jump
6th Aug 2021 07:22
(Sharecast News) - Hikma Pharmaceuticals upgraded full-year guidance for its generics arm and reported a rise in first-half profit and revenue as it hailed a strong performance in both the generics and branded segments, and resilience in the injectables business.
Read moreTuesday broker round-up
8th Jun 2021 13:54
(Sharecast News) - tinyBuild: Berenberg reiterates buy with a target price of 295p.
Read moreHikma predicts generics revenue at top of guidance
30th Apr 2021 07:38
(Sharecast News) - Hikma Pharmaceutical said it made a good start to 2021 and that annual revenue from generic treatments would be at the top of guidance.
Read moreHikma resumes US launch of 'Advair Diskus' generic
21st Apr 2021 07:30
(Sharecast News) - Hikma Pharmaceuticals has resumed the launch of its generic version of GlaxoSmithKline's 'Advair Diskus' in the United States, it announced on Wednesday, following Food and Drug Administration (FDA) approval of an amendment it submitted to its Abbreviated New Drug Application in January.
Read moreWednesday broker round-up
31st Mar 2021 13:40
(Sharecast News) - Hikma: Jefferies upgrades to buy with a target price of 2,870p.
Read moreJefferies upgrades Hikma to 'buy'
31st Mar 2021 11:56
(Sharecast News) - Analysts at Jefferies upgraded drugmaker Hikma Pharmaceuticals from 'hold' to 'buy' on Wednesday, stating the group's share price was yet to reflect "a series of upcoming product catalysts".
Read moreFriday broker round-up
26th Mar 2021 13:40
(Sharecast News) - Ocado Group: Berenberg downgrades to hold with a target price of 2,390p.
Read moreTalks between Hikma and GlaxoSmithKline fail to secure a deal
11th Mar 2021 13:50
(Sharecast News) - Talks between Hikma Pharmaceutical and drugs giant GlaxoSmithKline have ended, the generics group confirmed on Thursday.
Read moreMonday broker round-up
1st Feb 2021 13:44
(Sharecast News) - Polymetal International: Berenberg reiterates buy with a target price of 2,310p.
Read moreHikma rallies as it launches generic version of Glaxo asthma treatment
18th Dec 2020 08:12
(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.
Read moreWednesday broker round-up
2nd Dec 2020 13:11
(Sharecast News) - Royal Dutch Shell A: JP Morgan upgrades to overweight with a target price of 1,700p.
Read moreTuesday broker round-up
24th Nov 2020 13:33
(Sharecast News) - Glencore: Jefferies upgrades to buy with a target price of 250p.
Read moreTuesday broker round-up
10th Nov 2020 13:17
(Sharecast News) - On the Beach: Citigroup downgrades to neutral with a target price of 370p.
Read moreHikma raises FY guidance for generics unit following positive H1 momentum
5th Nov 2020 09:15
(Sharecast News) - Pharmaceutical company Hikma said on Thursday that the group as a whole was "performing well" and had maintained the positive momentum seen in the first half, leading it to reiterate guidance for one unit and raise it on another.
Read more